Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT03492125 is registered in ClinicalTrials.gov with MingSight Pharmaceuticals, Inc as lead sponsor.

NCT NCT03492125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03492125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Lead sponsor
MingSight Pharmaceuticals, Inc
Phase
Phase 1/2
Overall status
Terminated
Start date
May 25, 2018
Completion date
November 28, 2023
Enrollment
60 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma